Table 1 Baseline patient demographics and clinical characteristics
From: Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial
Characteristic | Usual Care (N = 22) | Intervention (N = 19) |
|---|---|---|
Sex, n (%) | ||
 Female | 9 (41%) | 8 (42%) |
 Male | 13 (59%) | 11 (58%) |
Age (years), median (Q1, Q3) | 60.0 (50.0, 66.0) | 59.0 (51.0, 81.0) |
Race, n (%) | ||
 Asian | 2 (9%) | 0 (0%) |
 Black or African American | 0 (0%) | 2 (10.5%) |
 Unknown/Not Reported | 3 (14%) | 2 (10.5%) |
 White | 17 (77%) | 15 (79%) |
BMI (kg/m2), median (Q1, Q3) | 32.3 (28.5, 39.1) | 30.8 (27.2, 39.9) |
Saturation/FIO2 Ratio | 332 (267.4, 430.5) | 339 (250, 423) |
Oxygen delivery at randomization, n (%) | ||
 HFNC | 7 (32%) | 3 (16%) |
 Mechanical ventilation | 1 (4%) | 1 (5%) |
 Nasal Cannula | 14 (64%) | 11 (58%) |
 Room air | 0 (0%) | 4 (21%) |
COPD, n (%) | 0 (0%) | 0 (0%) |
Admitted to ICU at randomization, n (%) | 10 (45%) | 4 (21%) |
Sepsis, n (%) | 0 (0%) | 0 (0%) |
Diabetes, n (%) | 5 (23%) | 4 (21%) |
Asthma, n (%) | 4 (18%) | 1 (5%) |
Home oxygen use, n (%) | 0 (0%) | 0 (0%) |
Dementia, n (%) | 0 (0%) | 1 (5%) |